Ray Manneh
Overview
Explore the profile of Ray Manneh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
58
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrylak D, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401283.
PMID: 40043230
Purpose: The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov...
2.
Pierre M, Manneh R, Hernandez A, Rodriguez J, Fletcher A, Ramirez H, et al.
Rev Colomb Obstet Ginecol
. 2024 Jul;
75(1).
PMID: 39013199
Introduction and objective: The approach to patients with advanced or metastatic high-grade epithelial ovarian cancer (EOC) has evolved over time with the advent of new therapies and multimodal strategies. The...
3.
Sierra-Diaz D, Morel A, Fonseca-Mendoza D, Contreras Bravo N, Molano-Gonzalez N, Borras M, et al.
Hum Genomics
. 2024 Jun;
18(1):68.
PMID: 38890714
Background: In Colombia and worldwide, breast cancer (BC) is the most frequently diagnosed neoplasia and the leading cause of death from cancer among women. Studies predominantly involve hereditary and familial...
4.
Incorvaia L, Marques Monteiro F, Massari F, Park S, Roviello G, Fiala O, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):142.
PMID: 38832989
Background: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune...
5.
Manneh R, Verson C, Martin A, Delgado A, Isaacsson Velho P, Manduley A, et al.
JCO Precis Oncol
. 2024 May;
8:e2300628.
PMID: 38748947
Purpose: The prevalence of homologous recombination repair gene mutations (HRRm) in patients with metastatic castration-resistant prostate cancer (mCRPC) in Latin America and the Caribbean (LAC) is unknown. Prevalence of homologous...
6.
Soares A, Bourlon M, Wong A, Joshi A, Jardim D, Korbenfeld E, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):467-475.
PMID: 38228413
Urothelial carcinoma (UC) is the 10 most common cancer globally with an almost 4 times higher prevalence in men. The main risk factors for development of urothelial carcinoma are advanced...
7.
Fiala O, Buti S, Takeshita H, Okada Y, Massari F, Palacios G, et al.
Cancer Immunol Immunother
. 2023 Sep;
72(11):3665-3682.
PMID: 37676282
Background: Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of...
8.
Ospina A, Bruges R, Triana I, Sanchez-Vanegas G, Barrero A, Mantilla W, et al.
J Cancer
. 2023 Sep;
14(13):2410-2416.
PMID: 37670962
During the pandemic, it has been recommended that vaccination against COVID-19 be a priority for patients with cancer; however, these patients were not included in the initial studies evaluating the...
9.
Lujan M, Lema M, Preciado B, Lema C, Egurrola J, Cardona A, et al.
J Investig Med
. 2023 Feb;
71(5):502-510.
PMID: 36760084
Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy in terms of survival...
10.
Carril-Ajuria L, Colomba E, Romero-Ferreiro C, Cerbone L, Ratta R, Barthelemy P, et al.
Eur J Cancer
. 2022 Dec;
180:21-29.
PMID: 36527973
Background: Immune checkpoint inhibitor-based combination therapy (ICI-based combination) is a new standard of care for metastatic clear cell renal cell carcinoma (mRCC) in the frontline setting. Patients with poor performance...